Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGB-19 Phase III study in active rheumatoid arthritis with inadequate methotrexate response
jRCT2031220512Phase 3Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of HS628 and tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoint: Mean change from baseline in DAS28-ESR at Week 12. Started Jan 2023; status: completed.
02
Drugs
HS628tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2031220512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220512.